Top 20 Life Science VC Funds & Investors in Norway (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Investinor
VC Fund
|
3 | Norway, United States, Sweden | Series A, Seed | Software, Biotechnology, Manufacturing | $400k–$25M |
|
Hadean Ventures
VC Fund
|
2 | Norway, Sweden, Germany | Series A, Series B | Biotechnology, Health Care, Medical | $4.3M–$79M |
|
Canica
VC Fund
|
2 | Norway, Denmark, Switzerland | Private Equity, Series A, Series D | Beauty, Retail, Medical | $7M–$25M |
|
Sandwater
VC Fund
|
1 | Norway, Germany, France | Series A, Seed | AgTech, Medical, Agriculture | $7.7M–$36M |
|
Project Sandwater
VC Fund
|
1 | Norway, The Netherlands | Series A | Medical, Consulting, Life Science | $11M–$17M |
|
SINTEF Venture AS
VC Fund
|
1 | Norway, United States, United Kingdom | Seed, Pre-Seed | Software, Manufacturing, Energy | $160k–$5.1M |
|
The Index Project
VC Fund
|
1 | United States, Denmark, Chile | Seed, Series A, Series B | Chemical, Artificial Intelligence, SaaS | $1.1M–$3M |
|
Qomel
VC Fund
|
1 | Norway | Seed | Life Science, Biotechnology | |
|
Wa’ed Ventures
VC Fund
|
1 | Saudi Arabia, United Arab Emirates, United States | Seed, Series A | Software, Information Technology, Artificial Intelligence | $600k–$28M |
|
Sofinnova Partners
VC Fund
|
1 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
World Wildlife Fund
VC Fund
|
1 | Norway, Faroe Islands, United Kingdom | Seed, Series A | Seafood, Food Processing, Farming | $1.9M–$6.2M |
|
Bakken & Baeck
VC Fund
|
1 | Norway | Seed, Angel | Chemical, Software, Life Science | |
|
Birk Venture
VC Fund
|
1 | Norway, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | $1.2M–$22M |
|
M Ventures
VC Fund
|
1 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Dynamk Capital
VC Fund
|
1 | United States, Canada, Norway | Series A, Seed, Series B | Biotechnology, Medical, Health Care | |
|
H2O Holding AS
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
Lekh Corp AS
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
|
NantBio
VC Fund
|
1 | Norway | Seed | Life Science, Biotechnology | |
|
Nordic Impact
VC Fund
|
1 | Norway | Seed | Chemical, Life Science, Visual Search | |
|
ERM Invest
VC Fund
|
1 | Norway | Pre-Seed | Software, Health Care, Life Science | |
| Access all 31 VC funds in Norway Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Manufacturing
- Stage:Series A, Seed
- Geography: Norway, United States, Sweden
Investor stats
- Total investments: 117
- Round size: Seed $400k–$3.3M; Series A $2M–$25M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $148M in 2011
Portfolio highlights
- Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Kongsberg Ferrotech — Kongsberg Ferrotech offers game-changing robotic services for inspection, repair, and maintenance (IRM) of underwater installations
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Norway, Sweden, Germany
Investor stats
- Total investments: 27
- Round size: Series A $4.3M–$79M; Series B $28M–$68M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $105M in 2021
Portfolio highlights
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- Emergence Therapeutics — Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as anADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.
Show more...Investment focus
- Industry: Beauty, Retail, Medical
- Stage:Private Equity, Series A, Series D
- Geography: Norway, Denmark, Switzerland
Investor stats
- Total investments: 10
- Round size: Series A $7M–$25M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
- Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
We are Sandwater. Regeneration of our resources. Vitalizing healthcare & education. Improving life through technology.
Show more...Investment focus
- Industry: AgTech, Medical, Agriculture
- Stage:Series A, Seed
- Geography: Norway, Germany, France
Investor stats
- Total investments: 17
- Round size: Series A $7.7M–$36M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- Mantle8 — Using bottom-up exploration and decades of geology experience, we are on a mission to deliver natural hydrogen to the world.
- XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
- Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.
Project Sandwater is a fresh take on venture investments within the Nordics and beyond.
Show more...Investment focus
- Industry: Medical, Consulting, Life Science
- Stage:Series A
- Geography: Norway, The Netherlands
Investor stats
- Total investments: 2
- Round size: Series A $11M–$17M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
We commercialize technology created by SINTEF's research environments
Show more...Investment focus
- Industry: Software, Manufacturing, Energy
- Stage:Seed, Pre-Seed
- Geography: Norway, United States, United Kingdom
Investor stats
- Total investments: 28
- Round size: Seed $160k–$5.1M; Pre-Seed $373k–$762k
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $51M in 2018
Portfolio highlights
- Nomono — Capture studio-quality podcasts with immersive 3D audio. Get professional mics, AI editing, and cloud storage in one system. Start your free trial today.
- Hystar — Hystar develops polymer electrolyte membrane electrolyzers designed for large-scale green hydrogen production. Founded in 2020, Hystar's technology uses a unique cell design and process architecture that provides the ability to reduce electricity consumption and increase hydrogen output, enabling professionals to tackle various criticalenergy challenges and having the potential to reduce greenhouse gas emissions.
- Hydrogen Mem-Tech — Hydrogen Mem-Tech aim is to make the green shift happen through our state-of-the-art hydrogen separation technology with carbon capture.
Design to improve life is about solving real problems, small and large, simple and complex, systemic and emerging and is a life-long pursuit. The Index Project is a call to action. Are you in?
Show more...Investment focus
- Industry: Chemical, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Chile
Investor stats
- Total investments: 9
- Round size: Seed $1.5M–$2M; Series A $1.1M–$3M
- Lead/follow: 0% lead, 100% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Agribuddy — Management of agricultural support application "AGRIBUDDY".
- CanopyLAB — CanopyLAB is an educational technology company located in Hvidovre, Greater Copenhagen, Denmark. We have built an AI-powered social learning platform for corporate training. Through personalization our platform enables all learners to realize their potential in a way that is fast, fun and future-proof. We call it "The Future of Learning-Delivered Today".We work on two verticals:1. The Canopy A social learning platform powered by AI A research-based social learning platform for developing competencies through individualized and adaptive learning experiences. It is designed with an integrated social network structure to enhance collaborative learning and built on strong Nordic learning principles.2. The LAB A learning community with provocative content Join our global learning community for youth. Take free courses, exchange ideas, gain new knowledge and practice competencies offered by 100 + pioneering NGOs in controversial and often neglected topics such as sexuality, sexual & reproductive rights, climate action, health, and the SDGs.CanopyLAB acquired Peruvian publishing startup Yopublico in April 2020.
- Destácame — Destacame is the first behavior-based credit score in Latin America.
Qomel Company is a healthcare and pharmaceutical services company that offers medical, diagnostic, and product distribution services. It operates ophthalmology, dental, wound care, and general medical services, while distributing pharmaceuticals and medical devices through warehouses and sales offices.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.
Wa’ed Ventures is a $500 million venture capital fund with the aim to accelerate the development of an integrated startup ecosystem by investing in local tech-based startups and incentivizing global entrepreneurs to localize their tech innovations in the Kingdom.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A
- Geography: Saudi Arabia, United Arab Emirates, United States
Investor stats
- Total investments: 90
- Round size: Seed $600k–$6.5M; Series A $2M–$28M
- Lead/follow: 61% lead, 39% follow
Portfolio highlights
- YNMO — YNMO is the first Arabic/English digital solution that aims to improve the quality of care and educational services for individuals with special needs by allowing service providers such as schools, centers & clinics to design and monitor individualized treatment plans.
- Hazen.ai — Enhance safety with our AI-powered camera, providing real-time monitoring and precise violation detection. This technology empowers authorities to enforce traffic laws effectively, ensuring safer roads for all.
- FalconViz — FalconViz is a Saudi registered company focused on 3D surveying and mapping by Unmanned Aerial Systems (UAS) with autonomous integration of planes, copters and 3D software solutions.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.
Show more...Investment focus
- Industry: Seafood, Food Processing, Farming
- Stage:Seed, Series A
- Geography: Norway, Faroe Islands, United Kingdom
Investor stats
- Total investments: 7
- Round size: Seed $1.9M–$4.7M; Series A $4.5M–$6.2M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- SeaForester — Restoring the forgotten forests in our ocean.
- Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
- Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.
Since 2011, we have built products with some of the most ambitious companies out there. From defining the future of conversational AI with Sierra to building decentralised platforms with Coinbase.
Show more...Investment focus
- Industry: Chemical, Software, Life Science
- Stage:Seed, Angel
- Geography: Norway
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
- Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Norway, United Kingdom
Investor stats
- Total investments: 9
- Round size: Series A $1.2M–$22M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
- Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
- Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 163
- Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Norway
Investor stats
- Total investments: 20
- Lead/follow: no public data
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
- Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.
Investment
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.
Investment Company
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.
NantBio offers treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.
Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.
Show more...Investment focus
- Industry: Chemical, Life Science, Visual Search
- Stage:Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications
Investment Company
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Pre-Seed
- Geography: Norway
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.
Life Science VC funding in Norway at a glance
Stats across 24 deals from 31 investors.
Access all 31 VC funds in Norway Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in Norway investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 31 VC funds investing in Norway Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!